financetom
Market
financetom
/
Market
/
Top stock recommendations by Ashwani Gujral, Mitessh Thakkar, Prakash Gaba for Friday
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Top stock recommendations by Ashwani Gujral, Mitessh Thakkar, Prakash Gaba for Friday
Dec 19, 2019 11:15 PM

Indian benchmark indices BSE Sensex and NSE’s Nifty50 are expected to open little changed on Friday tracking muted trends in global markets amid thin trades due to the upcoming holiday season.

Share Market Live

NSE

Among stocks, Ashwani Gujral is bullish on JSPL, Bharti Airtel, Eicher Motors, Escorts, and Avanti Feeds. Mitessh Thakkar is positive on Balrampur Chini, Hero MotoCorp, and Siemens and negative on L&T Finance Holdings. Prakash Gaba has 'buy' calls on Escorts, JSPL, Siemens, and SRF.

Here are the top buy-sell calls by market experts for Friday:

Ashwani Gujral - ashwanigujral.com

- Buy JSPL with a stop loss of Rs 150, target at Rs 162

- Buy Bharti Airtel with a stop loss of Rs 445, target at Rs 470

- Buy Eicher Motors with a stop loss of Rs 22,000, target at Rs 23,200

- Buy Escorts with a stop loss of Rs 622, target at Rs 640

- Buy Avanti Feeds with a stop loss of Rs 570, target at Rs 605

Mitessh Thakkar - mitesshthakkar.com

- Buy Balrampur Chini with a stop loss of Rs 172, target at Rs 184

- Sell L&T Finance Holdings with a stop loss of Rs 118, target at Rs 109

- Buy Hero MotoCorp with a stop loss of Rs 2,334, target at Rs 2,430

- Buy Siemens with a stop loss of Rs 1,503, target at Rs 1,575

Prakash Gaba - prakashgaba.com

- Buy Escorts with a stop loss of Rs 615, target at Rs 650

- Buy JSPL with a stop loss of Rs 149, target at Rs 162

- Buy Siemens with a stop loss of Rs 1,510, target at Rs 1,565

- Buy SRF with a stop loss of Rs 3,300, target at Rs 3,500

Also, track all live market action on CNBC-TV18 Market Blog

Disclaimer: CNBCTV18.com advises users to check with certified experts before taking any investment decisions

First Published:Dec 20, 2019 8:15 AM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sector Update: Financial
Sector Update: Financial
Jun 20, 2024
09:01 AM EDT, 06/20/2024 (MT Newswires) -- Financial stocks were edging higher pre-bell Thursday with the Financial Select Sector SPDR Fund (XLF) 0.02% higher recently. The Direxion Daily Financial Bull 3X Shares (FAS) was up 0.5% and its bearish counterpart Direxion Daily Financial Bear 3X Shares (FAZ) was 0.3% lower. Carlyle Group ( CG ) was up more than 1%...
Sector Update: Tech
Sector Update: Tech
Jun 20, 2024
08:54 AM EDT, 06/20/2024 (MT Newswires) -- Technology stocks were edging higher pre-bell Thursday with the Technology Select Sector SPDR Fund (XLK) marginally advancing and the SPDR S&P Semiconductor ETF (XSD) up 0.3% recently. The UK's Competition and Markets Authority said it is launching a probe of Hewlett-Packard's ( HPE ) $14 billion acquisition of Juniper Networks (JPNR). Hewlett Packard...
NVIDIA Stock Gains Push Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday
NVIDIA Stock Gains Push Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday
Jun 20, 2024
08:15 AM EDT, 06/20/2024 (MT Newswires) -- The broad market exchange-traded fund SPDR S&P 500 ETF Trust ( SPY ) was up 0.4% and the actively traded Invesco QQQ Trust (QQQ) was 0.6% higher in Thursday's premarket activity pushed by the continued gains in NVIDIA's ( NVDA ) stock. US stock futures were mixed, with S&P 500 Index futures up...
Sector Update: Health Care
Sector Update: Health Care
Jun 20, 2024
08:58 AM EDT, 06/20/2024 (MT Newswires) -- Health care stocks were steady pre-bell Thursday as the Health Care Select Sector SPDR Fund (XLV) was down 0.2% while iShares Biotechnology ETF (IBB) was recently unchanged. Jazz Pharmaceuticals ( JAZZ ) was down more than 2% after saying its investigational therapy suvecaltamide did not meet its primary endpoint in a phase 2b...
Copyright 2023-2025 - www.financetom.com All Rights Reserved